WO2008085601A3 - Genemap of the human genes associated with asthma disease - Google Patents

Genemap of the human genes associated with asthma disease Download PDF

Info

Publication number
WO2008085601A3
WO2008085601A3 PCT/US2007/083522 US2007083522W WO2008085601A3 WO 2008085601 A3 WO2008085601 A3 WO 2008085601A3 US 2007083522 W US2007083522 W US 2007083522W WO 2008085601 A3 WO2008085601 A3 WO 2008085601A3
Authority
WO
WIPO (PCT)
Prior art keywords
genemap
asthma disease
genes associated
human genes
relates
Prior art date
Application number
PCT/US2007/083522
Other languages
French (fr)
Other versions
WO2008085601A2 (en
Inventor
John Verner Raelson
Walter Edward Bradley
Randall David Little
Bruno Paquin
Quynh Nguyen-Huu
Tim Keith
Pascal Croteau
Abdelmajid Belouchi
Rene Allard
Sophie Debrus
Eerdewegh Paul Van
Jonathan Segal
Helene Fournier
Original Assignee
Genizon Biosciences Inc
John Verner Raelson
Walter Edward Bradley
Randall David Little
Bruno Paquin
Quynh Nguyen-Huu
Tim Keith
Pascal Croteau
Abdelmajid Belouchi
Rene Allard
Sophie Debrus
Eerdewegh Paul Van
Jonathan Segal
Helene Fournier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genizon Biosciences Inc, John Verner Raelson, Walter Edward Bradley, Randall David Little, Bruno Paquin, Quynh Nguyen-Huu, Tim Keith, Pascal Croteau, Abdelmajid Belouchi, Rene Allard, Sophie Debrus, Eerdewegh Paul Van, Jonathan Segal, Helene Fournier filed Critical Genizon Biosciences Inc
Priority to CA002667476A priority Critical patent/CA2667476A1/en
Priority to EP07871349A priority patent/EP2082343A2/en
Publication of WO2008085601A2 publication Critical patent/WO2008085601A2/en
Publication of WO2008085601A3 publication Critical patent/WO2008085601A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Ecology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the selection of a set of poymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to asthma disease and/or their response to a particular drug or drugs.
PCT/US2007/083522 2006-11-02 2007-11-02 Genemap of the human genes associated with asthma disease WO2008085601A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002667476A CA2667476A1 (en) 2006-11-02 2007-11-02 Genemap of the human genes associated with asthma disease
EP07871349A EP2082343A2 (en) 2006-11-02 2007-11-02 Genemap of the human genes associated with asthma disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85600306P 2006-11-02 2006-11-02
US60/856,003 2006-11-02

Publications (2)

Publication Number Publication Date
WO2008085601A2 WO2008085601A2 (en) 2008-07-17
WO2008085601A3 true WO2008085601A3 (en) 2008-12-11

Family

ID=39609231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083522 WO2008085601A2 (en) 2006-11-02 2007-11-02 Genemap of the human genes associated with asthma disease

Country Status (3)

Country Link
EP (1) EP2082343A2 (en)
CA (1) CA2667476A1 (en)
WO (1) WO2008085601A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221066A1 (en) 2009-02-18 2010-08-25 Sanofi-Aventis Use of VgII3 activity modulator for the modulation of adipogenesis
CN102471800A (en) * 2009-07-03 2012-05-23 加的夫大学学院咨询有限公司 Diagnosis and treatment of alzheimer's disease
US9872857B2 (en) 2009-10-23 2018-01-23 The Translational Genomics Research Institutet Methods of using propentofylline to treat glioma and glioblastoma
US20110262426A1 (en) * 2009-10-23 2011-10-27 The Translational Genomics Research Institute Methods and kits used in identifying glioblastoma
ES2619569T3 (en) 2010-05-31 2017-06-26 University Hospital Of Basel Test method of infection or inflammation of the lower respiratory tract
DK2612152T3 (en) * 2010-08-31 2020-08-10 Otto-Von-Guericke-Universität Magdeburg PROCEDURE FOR DIAGNOSTIC INFECTIOUS PERITONITIS AND PREDICTING THE DIFFICULTY AND ITS RESULT IN PEOPLE
DK178879B1 (en) * 2012-05-26 2017-04-24 Hans Bisgaard Method of diagnosing asthma and other wheezing disorders.
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
DK3321280T3 (en) * 2016-11-10 2021-02-22 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts IMMUNE MODULATORS FOR REDUCING IMMUNE RESISTANCE IN A MELANOME AND OTHER PROLIFERATIVE DISEASES
WO2018087276A1 (en) * 2016-11-10 2018-05-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Or10h1 modulators and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119474A1 (en) * 1997-03-03 2002-08-29 Drazen Jeffrey M. Diagnosing asthma patients predisposed to adverse beta-agonist reactions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119474A1 (en) * 1997-03-03 2002-08-29 Drazen Jeffrey M. Diagnosing asthma patients predisposed to adverse beta-agonist reactions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DRYSDALE ET AL.: "Complex promoter and coding region beta2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 97, September 2000 (2000-09-01), pages 10483 - 10488, XP002213210 *
HOGERKORP ET AL.: "CD-44-stimulated human B cells express transcripts specifically involved in immunomodulation and inflammation as analyzed by DNA microarrays", BLOOD, vol. 101, March 2003 (2003-03-01), pages 2307 - 2313, XP008109776 *
MILLER ET AL.: "Life stress and diminished expression of genes encoding glucocorticoid receptor and beta2-adrenergic receptor in children with asthma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 103, April 2006 (2006-04-01), pages 5496 - 5501, XP008110743 *
PAHL ET AL.: "Pharmacogenomics of Asthma", CURRENT PHARMACEUTICAL DESIGN, vol. 12, September 2006 (2006-09-01), pages 3195 - 3206, XP008110720 *

Also Published As

Publication number Publication date
EP2082343A2 (en) 2009-07-29
WO2008085601A2 (en) 2008-07-17
CA2667476A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2008016356A3 (en) Genemap of the human genes associated with psoriasis
WO2008112177A3 (en) Genemap of the human genes associated with schizophrenia
WO2007025085A3 (en) Genemap of the human genes associated with crohn's disease
WO2008118258A8 (en) Genemap of the human genes associated with adhd
WO2008067195A8 (en) Genemap of the human genes associated with crohn's disease
WO2006138696A3 (en) Genemap of the human genes associated with longevity
WO2008085601A3 (en) Genemap of the human genes associated with asthma disease
WO2009026116A3 (en) Genemap of the human genes associated with longevity
WO2008014400A3 (en) Crohn disease susceptibility gene
WO2009039244A3 (en) Genemap of the human genes associated with crohn's disease
WO2008123901A3 (en) Genemap of the human genes associated with endometriosis
EP2639319A3 (en) Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
EP2581453A3 (en) Genetic Markers of Mental Illness
WO2008017038A3 (en) Methods for selecting medications
WO2007143752A3 (en) Targets in breast cancer for prognosis or therapy
WO2009064973A3 (en) Diagnostic kits and methods for scd or sca therapy selection
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
WO2008055196A3 (en) Genemap of the human genes associated with male pattern baldness
WO2006063703A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2005118845A3 (en) Use of a genetic modification in the human gnaq gene for predicting risk of disease, the course of a disease, and reaction to treatments
WO2008052016A3 (en) The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2004076690A3 (en) Use of a mutation in the human gnas gene for predicting risks of disease, courses of diseases, and for predicting the response to treatments of disease
EP2016197A4 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871349

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2667476

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007871349

Country of ref document: EP